Eisai (ESAIY) and Biogen (BIIB) announced an update on the ongoing regulatory review of the Marketing Authorization Application, MAA, for ...

Continued treatment with AXS-05, a combination of dextromethorphan and bupropion, significantly reduces the risk for recurrence of Alzheimer’s disease–related agitation, phase 3 results show.

An extended study after a primary trial supports using the anti-amyloid drug lecanemab (Leqembi) for up to 36 months in ...

Eisai/Biogen’s Leqembi (lecanemab) was fully approved in the US in July 2023, and Eli Lilly’s Kisunla (donanemab) in July ...

Blarcamesine is a sigma 1 receptor agonist which targets Alzheimer's pathology upstream of amyloid and tau pathology, ...

If approved, LMTX has the potential to become the first orally available disease-modifying therapy (DMT) in the UK.

SAN DIEGO -- Biomarker and cognitive data supported treatment with the anti-amyloid agent lecanemab (Leqembi) for up to 36 ...

A key theme at the AD/PD 2025 has been the safety profile of DMTs, focusing on the issue of ARIA, a significant side effect ...

Eisai & Biogen update on regulatory review of MAA for lecanemab for early Alzheimer’s disease by the European Commission: Tokyo Wednesday, April 2, 2025, 16:00 Hrs [IST] Eisai C ...

Eisai (TYO: 4523) and Biogen (Nasdaq: BIIB) today provided an update on the ongoing regulatory review of the Marketing ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the European Commission (EC) has decided to refer ...